Cover Image
市場調查報告書

全球成藥市場

Global Over-the-Counter (OTC) Drug Markets

出版商 Kalorama Information 商品編碼 243521
出版日期 內容資訊 英文 183 Pages
訂單完成後即時交付
價格
Back to Top
全球成藥市場 Global Over-the-Counter (OTC) Drug Markets
出版日期: 2018年01月23日 內容資訊: 英文 183 Pages
簡介

本報告提供全球成藥市場相關調查分析,市場概要,各市場區隔的市場分析,各地區的市場分析,主要企業簡介等系統性資訊。

第1章 摘要整理

第2章 簡介

第3章 OTC中樞神經系統藥

  • 市場摘要
  • 市場:各藥物市場區隔
  • 市場:各地區
    • 亞太地區
    • 歐洲
    • 南美
    • 中東、非洲
    • 北美

第4章 OTC皮膚用藥

  • 市場摘要
  • 市場:各藥物市場區隔
  • 市場:各地區
    • 亞太地區
    • 歐洲
    • 南美
    • 中東、非洲
    • 北美

第5章 OTC腸胃系統藥

  • 市場摘要
  • 市場:各藥物市場區隔
  • 市場:各地區
    • 亞太地區
    • 歐洲
    • 南美
    • 中東、非洲
    • 北美

第6章 OTC呼吸系統藥

  • 市場摘要
  • 市場:各藥物市場區隔
  • 市場:各地區
    • 亞太地區
    • 歐洲
    • 南美
    • 中東、非洲
    • 北美

第7章 OTC藥:各種治療分類

  • 市場摘要
  • 市場:各地區
    • 亞太地區
    • 歐洲
    • 南美
    • 中東、非洲
    • 北美

第8章 亞太地區的成藥市場

  • 地區概要
  • 成藥的銷售額和成長率
  • 市場:各治療分類

第9章 歐洲的成藥市場

  • 地區概要
  • 成藥的銷售額和成長率
  • 銷售額:各國
  • 市場:各治療分類

第10章 南美的成藥市場

  • 地區概要
  • 成藥的銷售額和成長率
  • 銷售額:各國
  • 市場:各治療分類

第11章 中東、非洲的成藥市場

  • 地區概要
  • 成藥的銷售額和成長率
  • 銷售額:各國
  • 市場:各治療分類

第12章 北美的成藥市場

  • 地區概要
  • 成藥的銷售額和成長率
  • 銷售額:各國
  • 市場:各治療分類

第13章 成藥的主要製造商

  • 概要
  • 競爭企業分析
  • 成藥市場形成的契約、合併、收購
  • 主要企業簡介
    • Bayer AG
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Mylan N.V.
    • Perrigo Company plc
    • Pfizer, Inc.
    • Procter & Gamble Company
    • Reckitt Benckiser Group Plc
    • Sanofi
    • 大正製藥集團

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: KLI15581138

The global over-the-counter (OTC) drug market is highly fragmented by region. This is largely due to differences in economic conditions, perception of self-medication, education, access to medical advice and products, demographics, product availability, and incidence of diseases and medical conditions. Global Over-the-Counter (OTC) Drug Markets discusses the global and regional OTC markets, including market data on the following:

  • Global Over-the-Counter Drug Market Analysis: 2017 to 2023
  • Top Twenty OTC Drug Markets, Country Market Share (%), 2017 (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia, Rest of World)
  • Total Pharmaceutical Markets: Prescription vs. Non-Prescription by Country, 2017 (% of total pharmaceutical market) (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia)
  • Global OTC Drug Market Analysis, Markets by Product Segment, 2017 to 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
  • OTC Drug Markets in Asia Pacific
  • OTC Drug Markets in Europe
  • OTC Drug Markets in Latin America
  • OTC Drug Markets in Middle East & Africa
  • OTC Drug Markets in North America

Over-the-counter (OTC), non-legend, and non-prescription are all adjectives describing drugs that an individual may purchase without a prescription. By definition, the FDA has found them to be safe for use without medical supervision. As the pharmaceutical industry has grown, patients have become more involved in health-care issues and now have taken some medical treatment into their own hands. This has provided an opportunity for pharmaceutical companies to invest in research and development of OTC drugs. Drugs included in OTC segments are pain relievers, cough and cold remedies, sleeping aids, antifungals, and other products approved for use as a self-medication product. For the purpose of this study, Kalorama Information divides and discusses OTC product markets in five general segments:

  • OTC Central Nervous System Agents (Analgesics, Anti-Inflammatories, and Other Central Nervous System Agents)
  • OTC Dermatological Agents (Acne Treatments, Antifungals/Antiinfectives, Hair Growth Remedies, Others)
  • OTC Gastrointestinal System Agents (Laxatives, Antacids, Antidiarrheals, H2 Antagonists, Proton Pump Inhibitors)
  • OTC Respiratory System Agents (Antihistamines, Decongestants, Cough Preparations, Other Respiratory Agents)
  • OTC Agents -- Various Therapeutic Classifications (Smoking Cessation Market, Contraceptive Drugs, Weight Management Drugs [OTC drugs, not dietary supplements], Overactive Bladder Treatments)

The regional coverage in Global OTC Drug Markets goes to the country level in North America, Asia Pacific, Europe, Latin America, Middle East & Africa, including the following:

  • North America OTC Drug Market Value by Country, 2017 and 2023 (Canada, United States, Rest of North America)
  • OTC Drug Markets in the United States by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Canada by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Asia Pacific OTC Drug Market Value by Country, 2017 and 2023 (Australia, China, India, Japan, Rest of Asia Pacific)
  • OTC Drug Markets in Japan by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in China by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in India by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Australia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Europe OTC Drug Market Value by Country, 2017 and 2023 (France, Germany, Italy, Poland, Russia, Spain, Turkey, United Kingdom)
  • OTC Drug Markets in Germany by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in France by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets In Russia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in The United Kingdom by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Italy by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Spain by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Poland by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Turkey by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Latin America OTC Drug Market Value by Country, 2017 and 2023 (Argentina, Brazil, Mexico, Venezuela, Rest of Latin America)
  • OTC Drug Markets in Brazil by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Mexico by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Argentina by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Venezuela by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Middle East & Africa OTC Drug Market Value by Country, 2017 and 2023 (Saudi Arabia, South Africa, Rest of Middle East & Africa)
  • OTC Drug Markets in South Africa by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • OTC Drug Markets in Saudi Arabia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Middle East & Africa OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers' level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
  • Middle East & Africa OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

The consumer healthcare market involves a range of large and small competitors. Although hundreds of companies compete in the world OTC drug market, a handful of companies secure leading positions. Many leading companies are taking advantage of new opportunities in developing regions, which is adding to the competitive landscape of the OTC market. Global OTC Drug Markets notes the leading suppliers' shares of the OTC drug market by revenues for 2017 and also includes in-depth profiles for the following companies:

  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Mylan
  • Perrigo Co.
  • Pfizer
  • Procter & Gamble
  • Reckitt Benckiser
  • Sanofi
  • Taisho Pharmaceutical

The report includes discussions of conditions often treated with OTC medicines, health statistics related to the industry, global populations, aging populations, populations by region and issues affecting the market as a whole. Information is presented as a global overview, with special emphasis on primary markets such as the United States, Japan, China, Germany, and other key markets. The market segments provide an overview of demographics, market estimates and market forecasts.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the global market at the manufacturers' level. The base year for data is 2017. Forecast data is provided through 2023. Competitive analysis is provided for the year 2017. The forecasted market analysis for 2017-2023 was largely based on impact of industry consolidation, demographic trends, new developments, and global expansion.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • BACKGROUND
  • SCOPE AND METHODOLOGY
  • SIZE AND GROWTH OF THE GLOBAL OTC MARKET
    • Figure 1-1: Global Over-the-Counter Drug Market Analysis: 2017 to 2023 (millions USD)
  • Global Markets
    • Figure 1-2: Top Twenty OTC Drug Markets, Country Market Share (%), 2017 (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia, Rest of World)
  • Leading Competitors

CHAPTER TWO: INTRODUCTION

  • BACKGROUND
  • DISTRIBUTION AND SAFETY ISSUES IN THE UNITED STATES
  • CONSUMER ADVERTISING AND PROMOTION
  • GLOBAL HEALTH
  • Global Life Expectancy
    • Table 2-1: Average Life Expectancy in Years by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela, Global Average)
    • Figure 2-1: Average Life Expectancy in Years by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
  • Global Trends in Birth Rates
    • Table 2-2: Crude Birth Rate per 1,000 Persons by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela, Global Average)
    • Figure 2-2: Crude Birth Rate per 1,000 Persons by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
  • Tobacco Use
    • Figure 2-3: Percent of Tobacco Users as a Percentage of Population by Country, 1990 vs. 2010 (%) (Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, South Africa, Spain, Turkey, United Kingdom, United States)
  • Obesity
    • Figure 2-4: Obesity Prevalence as a Percentage of Population by Country, 2006 vs. 2016 (%) (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
  • Declining Growth of the Global Population
    • Table 2-3: Global Population 1980 to 2050 (millions)
    • Figure 2-5: The Global Population, 1980-2050
    • Figure 2-6: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
  • PRESCRIPTION VS. OVER-THE-COUNTER INDUSTRY
    • Figure 2-7: Total Pharmaceutical Markets: Prescription vs. Non-Prescription by Country, 2017 (% of total pharmaceutical market) (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia)
  • OVER-THE-COUNTER DRUG PRODUCT SEGMENTS
    • Table 2-4: Global OTC Drug Market Analysis, Markets by Product Segment, 2017 to 2023 (in millions of dollars at the manufacturers' level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
    • Figure 2-8: Global OTC Drug Market Analysis, Markets by Product Segment, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • RX-TO-OTC SWITCH INDUSTRY
    • Table 2-5: Leading FDA approved Rx-to-OTC switches, 1994-2017
    • Figure 2-9: Number of New Rx-to-OTC Switches in the United States, per year 1976-2017
  • ECONOMIC TRENDS
    • Figure 2-10: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, 2010 and 2020 Estimated (%) (United States, France, Germany, Canada, Japan, United Kingdom, Australia, Italy, Spain, South Africa, Brazil, Russia, Mexico, Poland, China, Venezuela, Turkey, India, Argentina, Saudi Arabia)
  • Purchasing Power Trends
    • Figure 2-11: Gross National Income by Country 1990-2010 and Estimated 2020 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
  • HEALTH INSURANCE ISSUES AND TRENDS: UNITED STATES
    • Figure 2-12: Number of Insured vs. Uninsured in the United States 2005-2016
    • Figure 2-13: Number of Insured Children vs. Uninsured Children in the United States 2005-2016
    • Figure 2-14: Number of Insured Children vs. Uninsured Children in the United States 2005-2016
  • CONSUMER ISSUES AND TRENDS
  • Access to Professional Medical Services and the Link to Self-Medication
    • Figure 2-15: Practicing Physicians per 1,000 Population by Country, 2017 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
  • REGULATORY SOLUTIONS TO OTC DRUG ACCESS
  • Revisions to Pharmaceutical Affairs Law (PAL) in Japan
    • Figure 2-16: Typical Pharmacist-Consumer OTC Drug Counseling Session
  • Changes to Australia's OTC Drug Access - Up-scheduling Combination Medicines Containing
  • Codeine
    • Figure 2-17: National Classification System of Scheduling Medicines

CHAPTER THREE: OVER-THE-COUNTER CENTRAL NERVOUS SYSTEM AGENTS

  • MARKET SUMMARY
    • Figure 3-1: Global OTC Central Nervous System Agent Market, 2017-2023
  • MARKET BY DRUG SEGMENT
    • Figure 3-2: Global OTC Central Nervous System Agent Market, Distribution of Sales by Drug Segment 2017 (%)
  • MARKETS BY REGION
  • Asia Pacific
    • Figure 3-3: Asia Pacific OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
  • Europe
    • Figure 3-4: Europe OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
  • Latin America
    • Figure 3-5: Latin America OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
  • Middle East & Africa
    • Figure 3-6: Middle East & Africa OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
  • North America
    • Figure 3-7: North America OTC Central Nervous System Agent Market, 2017-2023 ($ millions)

CHAPTER FOUR: OVER-THE-COUNTER DERMATOLOGICAL AGENTS

  • MARKET SUMMARY
    • Figure 4-1: Global OTC Dermatological Agent Market, 2017-2023
  • MARKET BY DRUG SEGMENT
    • Figure 4-2: Global OTC Dermatological Agent Market, Distribution of Sales by Drug Segment 2017 (%) (Acne
  • Treatments, Antifungals/Antiinfectives, Hair Growth Remedies, Others)
  • MARKETS BY REGION
  • Asia Pacific
    • Figure 4-3: Asia Pacific OTC Dermatological Agent Market, 2017-2023 ($ millions)
  • Europe
    • Figure 4-4: Europe OTC Dermatological Agent Market, 2017-2023 ($ millions)
  • Latin America
    • Figure 4-5: Latin America OTC Dermatological Agent Market, 2017-2023 ($ millions)
  • Middle East & Africa
    • Figure 4-6: Middle East & Africa OTC Dermatological Agent Market, 2017-2023 ($ millions)
  • North America
    • Figure 4-7: North America OTC Dermatological Agent Market, 2017-2023 ($ millions)

CHAPTER FIVE: OVER-THE-COUNTER GASTROINTESTINAL SYSTEM AGENTS

  • MARKET SUMMARY
    • Figure 5-1: Global OTC Gastrointestinal Agent Market, 2017-2023
  • MARKET BY DRUG SEGMENT
    • Figure 5-2: Global Gastrointestinal OTC Market, Distribution of Sales by Drug Segment 2017 (%) (Laxatives, Antacids, Antidiarrheals, H2 Antagonists, Proton Pump Inhibitors)
  • MARKETS BY REGION
  • Asia Pacific
    • Figure 5-3: Asia Pacific OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
  • Europe
    • Figure 5-4: Europe OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
  • Latin America
    • Figure 5-5: Latin America OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
  • Middle East & Africa
    • Figure 5-6: Middle East & Africa OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
  • North America
    • Figure 5-7: North America OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)

CHAPTER SIX: OVER-THE-COUNTER RESPIRATORY SYSTEM AGENTS

  • MARKET SUMMARY
    • Figure 6-1: Global OTC Respiratory Agent Market, 2017-2023
  • MARKET BY DRUG SEGMENT
    • Figure 6-2: Global OTC Respiratory Agent Market, Distribution of Sales by Drug Segment 2017 (%) (Antihistamines, Decongestants, Cough Preparations, Other Respiratory Agents)
    • Table 6-1: Global OTC Respiratory Agent Market, Sales by Indication, 2017-2023 ($ in millions) (Allergy/Asthma, Cough/Cold, Total)
    • Figure 6-3: Global OTC Respiratory Agent Market, Distribution of Sales by Indication 2017 (%) (Allergy/Asthma, Cough/Cold)
  • MARKETS BY REGION
  • Asia Pacific
    • Figure 6-4: Asia Pacific OTC Respiratory Agent Market, 2017-2023 ($ millions)
  • Europe
    • Figure 6-5: Europe OTC Respiratory Agent Market, 2017-2023 ($ millions)
  • Latin America
    • Figure 6-6: Latin America OTC Respiratory Agent Market, 2017-2023 ($ millions)
  • Middle East & Africa
    • Figure 6-7: Middle East & Africa OTC Respiratory Agent Market, 2017-2023 ($ millions)
  • North America
    • Figure 6-8: North America OTC Respiratory Agent Market, 2017-2023 ($ millions)

CHAPTER SEVEN: OVER-THE-COUNTER AGENTS3/4 VARIOUS THERAPEUTIC CLASSIFICATIONS

  • MARKET SUMMARY
    • Figure 7-1: Global OTC Other Therapies Market, 2017-2023
  • MARKETS BY REGION
  • Asia Pacific
    • Figure 7-2: Asia Pacific OTC Other Therapies Market, 2017-2023 ($ millions)
  • Europe
    • Figure 7-3: Europe OTC Other Therapies Market, 2017-2023 ($ millions)
  • Latin America
    • Figure 7-4: Latin America OTC Other Therapies Market, 2017-2023 ($ millions)
  • Middle East & Africa
    • Figure 7-5: Middle East & Africa OTC Other Therapies Market, 2017-2023 ($ millions)
  • North America
    • Figure 7-6: North America OTC Other Therapies Market, 2017-2023 ($ millions)

CHAPTER EIGHT: OTC DRUG MARKETS IN ASIA PACIFIC

  • REGIONAL OVERVIEW
    • Table 8-1: Asia Pacific Select Countries, Demographic Profile, 2017 and 2030 (Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Vietnam)
    • Figure 8-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Vietnam)
  • OTC DRUG SALES AND GROWTH IN ASIA PACIFIC MARKETS
    • Figure 8-2: OTC Drug Market in Asia Pacific Region, 2017-2023 (in millions of dollars at the manufacturers' level)
  • Sales for OTC Drug Markets by Country
    • Figure 8-3: Asia Pacific OTC Drug Market Value by Country, 2017 and 2023 (Australia, China, India, Japan, Rest of Asia Pacific)
    • Figure 8-4: Asia Pacific OTC Drug Markets by Country, 2017 (%) (Australia, China, India, Japan, Rest of Asia Pacific)
    • Figure 8-5: OTC Drug Markets in Japan by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
    • Figure 8-6: OTC Drug Markets in China by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
    • Figure 8-7: OTC Drug Markets in India by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
    • Figure 8-8: OTC Drug Markets in Australia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • ASIA PACIFIC OTC MARKETS BY THERAPEUTIC CLASS
    • Table 8-2: Asia-Pacific OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers' level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
    • Figure 8-9: Asia-Pacific OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER NINE: OTC DRUG MARKETS IN EUROPE

  • REGIONAL OVERVIEW
    • Table 9-1: Europe Select Countries, Demographic Profile, 2017 and 2030 (France, Germany, Italy, Poland, Russia, Spain, Sweden, Switzerland, Turkey, United Kingdom)
    • Figure 9-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (France, Germany, Italy, Poland, Russia, Spain, Sweden, Switzerland, Turkey, United Kingdom)
  • OTC DRUG SALES AND GROWTH IN EUROPE MARKETS
    • Figure 9-2: OTC Drug Market in Europe Region, 2017-2023 (in millions of dollars at the manufacturers' level)
  • SALES FOR OTC DRUG MARKETS BY EUROPEAN COUNTRY
    • Figure 9-3: Europe OTC Drug Market Value by Country, 2017 and 2023 (France, Germany, Italy, Poland, Russia, Spain, Turkey, United Kingdom)
    • Figure 9-4: Europe OTC Drug Markets by Country, 2017 (%) (France, Germany, Italy, Poland, Russia, Spain, Turkey, United Kingdom, Rest of Europe)
  • Germany
    • Figure 9-5: OTC Drug Markets in Germany by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • France
    • Figure 9-6: OTC Drug Markets in France by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Russia
    • Figure 9-7: OTC Drug Markets In Russia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • United Kingdom
    • Figure 9-8: OTC Drug Markets in The United Kingdom by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Italy
    • Figure 9-9: OTC Drug Markets in Italy by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Spain
    • Figure 9-10: OTC Drug Markets in Spain by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Poland
    • Figure 9-11: OTC Drug Markets in Poland by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Turkey
    • Figure 9-12: OTC Drug Markets in Turkey by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • EUROPE OTC MARKETS BY THERAPEUTIC CLASS
    • Table 9-2: Europe OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers' level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
    • Figure 9-13: Europe OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER TEN: OTC DRUG MARKETS IN LATIN AMERICA

  • REGIONAL OVERVIEW
    • Table 10-1: Latin America Select Countries, Demographic Profile, 2017 and 2030 (Argentina, Brazil, Chile, Mexico, Venezuela)
    • Figure 10-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Argentina, Brazil, Chile, Mexico, Venezuela)
  • OTC DRUG SALES AND GROWTH IN LATIN AMERICA MARKETS
    • Table 10-2: OTC Drug Market in Latin America Region, 2017-2023 (in millions of dollars at the manufacturers' level)
  • SALES FOR OTC DRUG MARKETS BY COUNTRY
    • Figure 10-2: Latin America OTC Drug Market Value by Country, 2017 and 2023 (Argentina, Brazil, Mexico, Venezuela, Rest of Latin America)
    • Figure 10-3: Latin America OTC Drug Markets by Country, 2017 (%) (Argentina, Brazil, Mexico, Venezuela, Rest of Latin America)
  • Brazil
    • Figure 10-4: OTC Drug Markets in Brazil by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Mexico
    • Figure 10-5: OTC Drug Markets in Mexico by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Argentina
    • Figure 10-6: OTC Drug Markets in Argentina by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Venezuela
    • Figure 10-7: OTC Drug Markets in Venezuela by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • LATIN AMERICA OTC MARKETS BY THERAPEUTIC CLASS
    • Table 10-3: Latin America OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers' level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
    • Figure 10-8: Latin America OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER ELEVEN: OTC DRUG MARKETS IN MIDDLE EAST & AFRICA

  • REGIONAL OVERVIEW
    • Table 11-1: Middle East & Africa Select Countries, Demographic Profile, 2017 and 2030 (Egypt, Iran, Israel, Saudi Arabia, South Africa, UAE)
    • Figure 11-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Egypt, Iran, Israel, Saudi Arabia, South Africa, UAE)
  • OTC DRUG SALES AND GROWTH IN MIDDLE EAST & AFRICA MARKETS
    • Figure 11-2: OTC Drug Market in Middle East & Africa Region, 2017-2023 (in millions of dollars at the manufacturers' level)
  • SALES FOR OTC DRUG MARKETS BY COUNTRY
    • Figure 11-3: Middle East & Africa OTC Drug Market Value by Country, 2017 and 2023 (Saudi Arabia, South Africa, Rest of Middle East & Africa)
    • Figure 11-4: OTC Drug Markets by Country, 2017 (%) (Saudi Arabia, South Africa, Rest of Middle East & Africa)
  • South Africa
    • Figure 11-5: OTC Drug Markets in South Africa by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Saudi Arabia
    • Figure 11-6: OTC Drug Markets in Saudi Arabia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • MIDDLE EAST & AFRICA OTC MARKETS BY THERAPEUTIC CLASS
    • Table 11-2: Middle East & Africa OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers' level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
    • Figure 11-7: Middle East & Africa OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER TWELVE: OTC DRUG MARKETS IN NORTH AMERICA

  • REGIONAL OVERVIEW
    • Table 12-1: North America Select Countries, Demographic Profile, 2017 and 2030 (Canada, United States)
    • Figure 12-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Canada, United States)
  • OTC DRUG SALES AND GROWTH IN NORTH AMERICA MARKETS
    • Figure 12-2: OTC Drug Markets in North America Region, 2017-2023 (in millions of dollars at the manufacturers' level)
  • Sales for OTC Drug Markets by Country
    • Figure 12-3: North America OTC Drug Market Value by Country, 2017 and 2023 (Canada, United States, Rest of North America)
    • Figure 12-4: North America OTC Drug Markets by Country, 2017 (%) (Canada, United States, Rest of North America)
  • United States
    • Figure 12-5: OTC Drug Markets in the United States by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • Canada
    • Figure 12-6: OTC Drug Markets in Canada by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
  • NORTH AMERICA OTC MARKETS BY THERAPEUTIC CLASS
    • Table 12-2: North America OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers' level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
    • Figure 12-7: North America OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)

CHAPTER THIRTEEN: LEADING OTC DRUG MANUFACTURERS

  • OVERVIEW
  • COMPETITOR ANALYSIS
    • Table 13-1: Leading Suppliers Shares of the OTC Drug Market by Revenues-2017
    • Figure 13-1: Leading Suppliers Shares of the OTC Drug Market, 2017
  • A DECADE OF AGREEMENTS, MERGERS AND ACQUISITIONS SHAPING THE OTC DRUG MARKET
    • Sanofi and Boehringer Ingelheim
    • GlaxoSmithKline and Novartis AG
    • Bayer AG and Merck & Co.
    • Prestige Brands and Insight Pharmaceuticals
    • Perrigo Company Acquisitions
    • Procter & Gamble and Teva Pharmaceutical Industries
    • Sanofi and Chattem Consumer
    • Wyeth and Pfizer
    • Reckitt Benckiser and Adams Respiratory Therapeutics
  • LEADING CORPORATE PROFILES
  • Bayer AG
    • Table 13-2: Bayer Corporate Summary
    • Table 13-3: Bayer Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December) .. 153
  • GlaxoSmithKline plc
    • Table 13-4: GlaxoSmithKline Corporate Summary
    • Table 13-5: GlaxoSmithKline Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
  • Johnson & Johnson
    • Table 13-6: Johnson & Johnson Corporate Summary
    • Table 13-7: Johnson & Johnson Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
  • Mylan N.V.
    • Table 13-8: Mylan Corporate Summary
    • Table 13-9: Mylan Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
  • Perrigo Company plc
    • Table 13-10: Perrigo Company Corporate Summary
    • Table 13-11: Perrigo Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
  • Pfizer, Inc.
    • Table 13-12: Pfizer Corporate Summary
    • Table 13-13: Pfizer Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
  • Procter & Gamble Company
    • Table 13-14: Procter & Gamble Company Corporate Summary
    • Table 13-15: Procter & Gamble Recent Revenue History, 2015-2017 (US$ Millions, financial year ending June)
  • Reckitt Benckiser Group Plc
    • Table 13-16: Reckitt Benckiser Group Corporate Summary
    • Table 13-17: Reckitt Benckiser Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
  • Sanofi
    • Table 13-18: Sanofi Corporate Summary
    • Table 13-19: Sanofi Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
  • Taisho Pharmaceutical Holding Co., Ltd.
    • Table 13-20: Taisho Pharmaceutical Holding Corporate Summary
    • Table 13-21: Taisho Pharmaceutical Recent Revenue History, FY End 2016-2017 (US$ Millions, financial year ending March)
Back to Top